Metabolic Fire

Tirzepatide + Cagrilintide — dual GIP/GLP-1 agonism combined with amylin analogue for metabolic research

Tirzepatide is the first approved dual GIP/GLP-1 receptor co-agonist (Mounjaro). Cagrilintide is a long-acting amylin analogue in late-stage trials. Amylin works via hindbrain area postrema receptors, complementary to GLP-1 receptor signalling. Phase 3 data for this combination (CagriSema) shows ~25% weight reduction — research into their combined mechanism drives significant academic interest.

Components (2)

Tirzepatide 5mg

Cagrilintide 5mg

≥99.5%

HPLC Purity

<0.5 EU/mg

Endotoxin

Lyophilised

Form

Lot-Tested

COA Included

$155.00